Backed by our proprietary high efficient AAV production platform, high throughput vector engineering platform, GMP level AAV manufacturing platform, Cure Genetics is dedicated in developing new AAV based, effective, long lasting therapeutic solutions for rare, life threatening diseases that don’t have a cure.
Currently, we have established multiple pipelines to treat rare diseases in retina, liver, muscle and autoimmune fields.
Advantage of AAV as a therapeutic tool
|● tissue tropisms: each serotypes have different transduction efficiency for tissues.|
|● relatively low immunogenicity: comparing to other viruses, AAV has relative low immunogenicity.|
|● non-pathogenicity: So far, there is no evidence linking AAV to any diseases.|